238 related articles for article (PubMed ID: 37142692)
1. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance.
Chibaya L; Murphy KC; DeMarco KD; Gopalan S; Liu H; Parikh CN; Lopez-Diaz Y; Faulkner M; Li J; Morris JP; Ho YJ; Chana SK; Simon J; Luan W; Kulick A; de Stanchina E; Simin K; Zhu LJ; Fazzio TG; Lowe SW; Ruscetti M
Nat Cancer; 2023 Jun; 4(6):872-892. PubMed ID: 37142692
[TBL] [Abstract][Full Text] [Related]
2. EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma.
Li CH; Xiao Z; Tong JH; To KF; Fang X; Cheng AS; Chen Y
Int J Cancer; 2017 Jan; 140(1):120-129. PubMed ID: 27594424
[TBL] [Abstract][Full Text] [Related]
3. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
[TBL] [Abstract][Full Text] [Related]
4. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
5. Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity.
Chen NM; Neesse A; Dyck ML; Steuber B; Koenig AO; Lubeseder-Martellato C; Winter T; Forster T; Bohnenberger H; Kitz J; Reuter-Jessen K; Griesmann H; Gaedcke J; Grade M; Zhang JS; Tsai WC; Siveke J; Schildhaus HU; Ströbel P; Johnsen SA; Ellenrieder V; Hessmann E
Gastroenterology; 2017 May; 152(6):1507-1520.e15. PubMed ID: 28188746
[TBL] [Abstract][Full Text] [Related]
6. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
[TBL] [Abstract][Full Text] [Related]
7. Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer.
Patil S; Forster T; Reutlinger K; Kopp W; Versemann L; Spitalieri J; Gaedcke J; Ströbel P; Singh SK; Ellenrieder V; Neesse A; Hessmann E
Cells; 2021 Dec; 10(12):. PubMed ID: 34943970
[TBL] [Abstract][Full Text] [Related]
8. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer.
Ruscetti M; Morris JP; Mezzadra R; Russell J; Leibold J; Romesser PB; Simon J; Kulick A; Ho YJ; Fennell M; Li J; Norgard RJ; Wilkinson JE; Alonso-Curbelo D; Sridharan R; Heller DA; de Stanchina E; Stanger BZ; Sherr CJ; Lowe SW
Cell; 2020 Apr; 181(2):424-441.e21. PubMed ID: 32234521
[TBL] [Abstract][Full Text] [Related]
9. Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination.
Yasuda T; Koiwa M; Yonemura A; Miyake K; Kariya R; Kubota S; Yokomizo-Nakano T; Yasuda-Yoshihara N; Uchihara T; Itoyama R; Bu L; Fu L; Arima K; Izumi D; Iwagami S; Eto K; Iwatsuki M; Baba Y; Yoshida N; Ohguchi H; Okada S; Matsusaki K; Sashida G; Takahashi A; Tan P; Baba H; Ishimoto T
Cell Rep; 2021 Feb; 34(8):108779. PubMed ID: 33626356
[TBL] [Abstract][Full Text] [Related]
10. Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma.
Han T; Zhuo M; Yuan C; Xiao X; Cui J; Qin G; Wang L; Jiao F
Cancer Biol Med; 2020 Nov; 17(4):953-969. PubMed ID: 33299646
[TBL] [Abstract][Full Text] [Related]
11. EZH2-shRNA-mediated upregulation of p21waf1/cip1 and its transcriptional enhancers with concomitant downmodulation of mutant p53 in pancreatic ductal adenocarcinoma.
Batchu RB; Qazi AM; Gruzdyn OV; Semaan A; Seward SM; Chamala S; Dhulipala VB; Bouwman DL; Weaver DW; Gruber SA
Surgery; 2013 Oct; 154(4):739-46; discussion 746-7. PubMed ID: 24074410
[TBL] [Abstract][Full Text] [Related]
12. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells.
Bugide S; Green MR; Wajapeyee N
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3509-E3518. PubMed ID: 29581297
[TBL] [Abstract][Full Text] [Related]
14. Regulation of pancreatic cancer therapy resistance by chemokines.
Gautam SK; Basu S; Aithal A; Dwivedi NV; Gulati M; Jain M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):69-80. PubMed ID: 36064086
[TBL] [Abstract][Full Text] [Related]
15. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.
Bugide S; Gupta R; Green MR; Wajapeyee N
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301901
[TBL] [Abstract][Full Text] [Related]
16. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
17. Removal of gemcitabine-induced senescent cancer cells by targeting glutaminase1 improves the therapeutic effect in pancreatic ductal adenocarcinoma.
Oyama K; Iwagami Y; Kobayashi S; Sasaki K; Yamada D; Tomimaru Y; Noda T; Asaoka T; Takahashi H; Tanemura M; Doki Y; Eguchi H
Int J Cancer; 2024 Mar; 154(5):912-925. PubMed ID: 37699232
[TBL] [Abstract][Full Text] [Related]
18. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of long noncoding RNA SNHG14 suppresses cell proliferation and invasion by regulating EZH2 in pancreatic ductal adenocarcinoma (PDAC).
Xie F; Huang Q; Wang C; Chen S; Liu C; Lin X; Lv X; Wang C
Cancer Biomark; 2020; 27(3):357-364. PubMed ID: 31929143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
